SINOTAUPHARMA-B (09941.HK): IPO Closes, Margin Demand Tops HK$ 169bn

On 19 November 2026, SINOTAUPHARMA-B (09941.HK) closed its public offer, drawing HK$ 169.6 billion in margin financing, some 3,801 times its retail tranche.

NewTimeSpace News: The Hong Kong public offer of Beijing Sinotau International Pharmaceutical Technology Co., Ltd. (stock code: 09941) closed on 19 November 2026. Based on market data, margin financing extended by 10 brokers totalled HK$ 169.596 billion as of 11:04 a.m., equivalent to about 3,801 times the HK$ 44.6 million retail tranche.

The company is offering 6,561,000 H shares, comprising 656,100 H shares under the Hong Kong public offer (subject to reallocation) and 5,904,900 H shares under the international offering, at an offer price of HK$ 52.00 to HK$ 68.00 per share. The board lot is 50 H shares, with an entry fee of about HK$ 3,434.29 at the maximum offer price, and gross proceeds of about HK$ 341 million to HK$ 446 million.

Sinotau develops and commercialises diagnostic and therapeutic radiopharmaceuticals, with end-to-end capabilities spanning radionuclide development and production, R&D, manufacturing and commercialisation, focusing on neurodegenerative diseases, cardiovascular diseases and oncology.

According to the global offering announcement, the company expects to publish the offer results no later than 23 November, with trading in the H shares expected to commence on the Stock Exchange on 24 November.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.